Open AccessEfficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study
Author(s) -
Zhu Haoyue,
Deng Xuejun,
Feng Li,
Lian Yajun,
Han Xiong,
Guo Zhenli,
Gou Yulan,
Du Yuanmin,
Xie Longshan,
Yao Dongai,
Liu Yonghong,
Wu Qiang,
Lan Song,
Liu Kaisheng,
Zhan Peiyan,
Wang Xiahong,
Dang Jingxia,
Hou Yunqi,
Chen Keqiang,
Zhu Yulan,
Shi Yuliang,
Yu Yunli,
Xiao Bo,
Zhu Suiqiang,
Meng Hongmei
Publication year - 2022
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13840
Subject(s) - oxcarbazepine , medicine , levetiracetam , epilepsy , quality of life (healthcare) , randomized controlled trial , anxiety , pediatrics , psychiatry , carbamazepine , nursing
Aims This multicenter, open‐label, randomized study (Registration No. ChiCTR‐OCH‐14004528) aimed to compare the efficacy and effects of oxcarbazepine (OXC) with levetiracetam (LEV) as monotherapies on patient quality of life and mental health for patients with newly diagnosed focal epilepsy from China. Methods Patients with newly diagnosed focal epilepsy who had experienced 2 or more unprovoked seizures at greater than a 24‐h interval during the previous year were recruited. Participants were randomly assigned to the OXC group or LEV group. Efficacy, safety, quality of life, and mental health were evaluated over 12‐week and 24‐week periods. Results In total, we recruited 271 newly diagnosed patients from 23 centers. Forty‐four patients were excluded before treatment for reasons. The rate of seizure freedom of OXC was significantly superior to that of LEV at 12 weeks and 24 weeks ( p < 0.05). The quality of life (except for the seizure worry subsection) and anxiety scale scores also showed significant differences from before to after treatment in the OXC and LEV groups. Conclusions OXC monotherapy may be more effective than LEV monotherapy in patients with newly diagnosed focal epilepsy. Both OXC and LEV could improve the quality of life and anxiety state in adult patients with focal epilepsy.